Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nycomed has reported that the FDA approved Alvesco inhalation aerosol in the US for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older.
Subscribe to our email newsletter
The decision of the FDA allows the product to be sold in the US, where it is patent protected until 2017. Nycomed is in active negotiations with possible marketing partners for the commercialization of Alvesco in the US.
Alvesco (ciclesonide) inhalation aerosol is a new generation of inhaled corticosteroid that reduces inflammatory processes and is indicated for the use in patients with asthma.
Myron Zitt, chief of allergy and immunology at the Queens Long Island Medical Group in Babylon, New York, said: “The approval of Alvesco provides a new and effective treatment option to help patients control their asthma and improve their quality of life, and will be an important treatment option for physicians.”